Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib;Sindrome de lisis tumoral en un paciente con cancer de riñon tratado con sunitinib

Medicina

Volumn 71, Issue 2, 2011, Pages 158-160

  Rodriguez Reimundes, Ezequiel ^a   Perazzo, Florencia ^b   Vilches, Antonio R ^a  

^a Departamento de Medicina   (Argentina)

^b CEMIC   (Argentina)

Author keywords

Acute renal failure; Sunitinib; Tumor lysis syndrome

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ARTICLE; CASE REPORT; DISEASE PREDISPOSITION; DRUG EFFECT; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY CARCINOMA; MALE; RECURRENT CANCER; TUMOR LYSIS SYNDROME; FATALITY; KIDNEY TUMOR; MIDDLE AGED;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FATAL OUTCOME; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; TUMOR LYSIS SYNDROME;

EID: 79958704937     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11.
2. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546-54.
3. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38: 4-8.
4. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008; 93: 1877-85.
5. Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008; 93: 9-13.
6. Pui CH, Mahmoud HH, Wiley JM. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
7. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007; 4: 83-93.
8. Segura Torres P, Borrego Utiel FJ, Pérez Del Barrio P, Gil Cunquero JM, Pérez Bañasco V. Eficacia de la rasburicasa en el fracaso renal agudo obstructivo por litiasis: una nueva opción terapéutica. Nefrología 2008; 28: 102-5.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115.
10. Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 2007; 25: 3544-6.
11. Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 2007; 369: 1923-4.
12. Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs 2010; 28: 690-3.